Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

Mattia Nigro; Stefano Aliberti

doi:10.1164/rccm.202508-2056vp

October 6, 2025American Journal of Respiratory and Critical Care MedicineOpen Access

Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

View Full Paper

Ask AI

Bookmark

Share

Key Points

Dipeptidyl peptidase-1 inhibitors may influence treatment outcomes in bronchiectasis, as explored in this analysis.
The study discusses treatment complexities, emphasizing the interdependence of various drugs in managing bronchiectasis.
Observational analysis of treatment impacts suggests that no drug operates in isolation, affecting bronchiectasis outcomes.
Understanding the role of dipeptidyl peptidase-1 inhibitors may inform future treatment strategies for bronchiectasis.

Implication

Analysis reveals potential roles of dipeptidyl peptidase-1 inhibitors in bronchiectasis, highlighting treatment complexities.

Abstract

"Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nigro et al. (2025) studied this question.

synapsesocial.com/papers/68e6679587ecc93a24d1748a https://doi.org/10.1164/rccm.202508-2056vp

View Full Paper

Ask AI

Bookmark

Share

Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

Key Points

Implication

Abstract

Discussion

Cite This Study

Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading